Experimental drug combo targets sarcoma before surgery

NCT ID NCT05116254

Terminated Disease control Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a drug called AZD1390, which blocks DNA repair, given with or without an immunotherapy (durvalumab) plus standard radiation before surgery for soft tissue sarcoma. The goal was to see if the combination is safe and tolerable, especially regarding wound healing after surgery. Only 12 people took part, and the study was stopped early, so results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD1390 (a drug that blocks DNA repair) combined with radiotherapy, and sometimes with durvalumab (an immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for soft tissue sarcoma that combines targeted drugs with standard radiotherapy.
What could go wrong: This was a very early (Phase 1) trial that was terminated early with only 12 participants. The combination may cause significant side effects, especially wound healing problems after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA ADULT

Contacts and locations

Locations

Antoni van Leeuwenhoek

Amsterdam, 1066CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.